PK and Safety Study of HCP1102, HGP0813 and HGP1408
NCT03371849
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
24
Enrollment
INDUSTRY
Sponsor class
Conditions
Healthy
Interventions
DRUG:
montelukast and levocetirizine FDC
DRUG:
Singulair + xyzal
Sponsor
Hanmi Pharmaceutical Company Limited